Skip to main content

Table 5 Ongoing trials using novel agents alone or in combination as front-line therapy for young MCL patients

From: Paramount therapy for young and fit patients with mantle cell lymphoma: strategies for front-line therapy

Trial Regimen Design Sponsor Identifier
Window IR with With Hyper-CVAD Consolidation Phase II, Open-Label M.D. Anderson Cancer Center NCT02427620
O-HyperCVAD/ O-MA Phase II, Open Label Roswell Park Cancer Institute NCT01527149
Triangle (1) R-CHOP /R-DHAP + ASCT
(2) R-CHOP+IBN/R-DHAP +ASCT +IBN maintenance ×2 ys
(3) R-CHOP+IBN/ R-DHAP + IBN maintenance × 2 ys
Phase III, Open-Label Prof. Dr. M. Dreyling NCT02858258
ECOG-ACRIN (EA4151) patients with MRD (−) after induction:
(1)ASCT + R maintenance Open-Label
(2) R maintenance without ASCT
Randomized Phase III, Open-Label ECOG-ACRIN Cancer Research Group NCT03267433
BDH-MCL01 R-EDOCH/R-DHAP→HDT/ASCT or R-EDOCH/R-DHAP→MR or MTp Phase III, Open-Label Institute of Hematology & Blood Diseases Hospital NCT02858804
IBNa Phase II, Open Label M.D. Anderson Cancer Center NCT03282396
BTZ retrospective and prospective Xian-Janssen Pharmaceutical Ltd. NCT03053024
VCR Phase II, Open-Label University of Arizona NCT00980395
BR/RAC Phase I, Open-Label Washington University School of Medicine NCT 02728531
R-CHOP14 → R-HIDAC→RIT → HDT → ASCT Phase I/II, Open-Label Memorial Sloan Kettering Cancer Center NCT 01484093
  1. Abbreviations as indicated in the Tables 1, 3 and 4
  2. Note: IR ibrutinib and rituximab, O-HyperCVAD/ O-MA Hyper-Fractionated Cyclophosphamide, Doxorubicin, Vincristine and Dexamethasone Alternating With Ofatumumab High-Dose Cytarabine and Methotrexate, R-EDOCH rituximab etoposide, dexamethasone, doxorubicin, cyclophosphamide, and vincristine, HDT high-dose chemotherapy, MR maintenance rituximab, MTp maintenance thalidomide and prednisone, BTZ Bortezomib, RCT Rituximab, Cladribine, and Temsirolimus, VCR Bortezomib (Velcade), Cladribine and Rituximab, RB Rituximab/Bendamustine, RAC Rituximab/Cytarabine, R-CHOP-14 rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone every 2 weeks, RIT radioimmunotherapy Iodine 131I Tositumomab
  3. afor the low-risk disease